Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.bbrc.2008.04.047
DC Field | Value | |
---|---|---|
dc.title | The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor | |
dc.contributor.author | Sharghi-Namini, S. | |
dc.contributor.author | Fan, H. | |
dc.contributor.author | Sulochana, K.N. | |
dc.contributor.author | Potturi, P. | |
dc.contributor.author | Xiang, W. | |
dc.contributor.author | Chong, Y.-S. | |
dc.contributor.author | Wang, Z. | |
dc.contributor.author | Yang, H. | |
dc.contributor.author | Ge, R. | |
dc.date.accessioned | 2014-10-27T08:42:25Z | |
dc.date.available | 2014-10-27T08:42:25Z | |
dc.date.issued | 2008-06-27 | |
dc.identifier.citation | Sharghi-Namini, S., Fan, H., Sulochana, K.N., Potturi, P., Xiang, W., Chong, Y.-S., Wang, Z., Yang, H., Ge, R. (2008-06-27). The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor. Biochemical and Biophysical Research Communications 371 (2) : 215-219. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bbrc.2008.04.047 | |
dc.identifier.issn | 0006291X | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/101909 | |
dc.description.abstract | Angiogenesis is critical for tumour growth and metastasis where factors that regulate this process are potential targets for development of anti-cancer drugs. In this study, we show that the first TSR domain of the extracellular matrix protease ADAMTS5, unlike the second TSR, has anti-angiogenic activities where it inhibits endothelial cell tube formation on Matrigel, reduces cell proliferation and attachment, while promoting cell apoptosis and migration, all in a dose-dependent manner. Furthermore, it influences the architecture of endothelial cells by disrupting actin stress fibres and reducing focal adhesions, likely via suppressing RhoA activation. TSR1 of ADAMTS5 is therefore a novel anti-angiogenic peptide and could serve as a prototype for future development into anti-cancer drugs. © 2008 Elsevier Inc. All rights reserved. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.bbrc.2008.04.047 | |
dc.source | Scopus | |
dc.subject | ADAMTS5 | |
dc.subject | Angiogenesis | |
dc.subject | TSR | |
dc.subject | VEGF | |
dc.type | Article | |
dc.contributor.department | BIOLOGICAL SCIENCES | |
dc.description.doi | 10.1016/j.bbrc.2008.04.047 | |
dc.description.sourcetitle | Biochemical and Biophysical Research Communications | |
dc.description.volume | 371 | |
dc.description.issue | 2 | |
dc.description.page | 215-219 | |
dc.description.coden | BBRCA | |
dc.identifier.isiut | 000256049700008 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.